# IMG Pharma Enters into Definitive Agreement to Acquire Matsumoto Pharmaceutical

- Link: https://www.thailand-business-news.com/pr-news/img-pharma-enters-into-definitive-agreement-to-acquire-matsumoto-pharmaceutical
- Published: 2026-04-27T15:35:00+07:00
- Author: PR Newswire

TOKYO, April 27, 2026 /PRNewswire/ — IMG Pharmaceutical Co., Ltd. ("IMG Pharma"),
a majority-owned subsidiary of IMG Japan, the Group’s holding company, announced
that it has entered into a definitive agreement to acquire Matsumoto Pharmaceutical
Co., Ltd., a Japanese pharmaceutical manufacturer.

IMG Medical Group operates an integrated healthcare platform across Asia, providing
structured clinical services and long-term health management across the full lifecycle
of care—from life creation and optimization to preservation. Within this framework,
IMG Pharma serves as the Group’s pharmaceutical and product platform, translating
clinical needs and medical pathways into standardized, scalable pharmaceutical and
health products.

Founded in 1948, Matsumoto Pharmaceutical has established a mature OTC product system,
with more than 50 registered drug approvals across Class 1, 2, and 3 categories 
and over 30 trademarks. Its product portfolio spans digestive, respiratory, and 
dermatological areas, as well as metabolic and physiological function-related segments.

Matsumoto Pharmaceutical currently operates two pharmaceutical manufacturing facilities
in the Kansai region, with a combined site area exceeding 10,000 square meters, 
supporting its established production and OTC manufacturing capabilities.

IMG Pharma operates with Kobe as its core R&D and industrialization hub, leveraging
the Kobe Biomedical Innovation Cluster (KBIC), one of Japan’s leading life science
ecosystems. The Company is advancing research and product development across regenerative
and bioactive domains, including DPSC (dental pulp stem cell-related pathways), 
iPS cell-related technologies, placenta-derived bioactive components, and NAD-related
compounds, with a focus on translational development and productization.

This integration combines IMG Pharma’s biopharmaceutical and translational capabilities
with Matsumoto Pharmaceutical’s manufacturing foundation and OTC product system,
forming a multi-layered product capability structure. It is expected to support 
the development of a scalable pharmaceutical and health product platform addressing
long-term health management needs.

"This agreement is not only an important step in strengthening IMG Pharma’s pharmaceutical
and product platform, but also reflects our broader approach to building a structured
system that connects scientific innovation with real-world healthcare applications,"
said Yuki Sakurai, CEO of IMG Pharma.

"By integrating Kobe-based R&D and translational capabilities with Matsumoto Pharmaceutical’s
established manufacturing and OTC system, we are creating a more scalable pathway
from clinical care to product-based health solutions, with a continued focus on 
long-term health management."

About IMG Pharma

IMG Pharmaceutical Co., Ltd. is a pharmaceutical company and a majority-owned subsidiary
of IMG Japan. It serves as the Group’s product and pharmaceutical platform, focusing
on the development, manufacturing, and commercialization of pharmaceutical and functional
health products.

About IMG Japan

IMG Japan is an integrated healthcare platform operating across Asia, connecting
clinical services, regenerative medicine, and healthcare product development to 
support long-term health management.

About Matsumoto Pharmaceutical

Matsumoto Pharmaceutical Co., Ltd., established in 1948, is a Japanese pharmaceutical
manufacturer with a long history in OTC drug development and production.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [IMG Pharma Enters into Definitive Agreement to Acquire Matsumoto Pharmaceutical ](http://www.prnasia.com/story/archive/4943919_AE43919_0?rand=184833)